Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

FrankieSmilez Dec. 1 at 7:55 AM

$PFE $MRNA $NVAX $SPY $JNJ Six years ago today, on December 1st, 2019, a guy in Wuhan, China, started showing symptoms and became the first known case of COVID-19. Since then, there have been more than 778 million confirmed cases and 7.1 million deaths. Now, on December 1st, 2025, they're reporting that COVID-19 shots can kill children. It's wild how much has happened and how much has changed in these past six years. https://abcnews.go.com/US/fda-links-10-childrens-deaths-covid-19-vaccines/story?id=127985834

1 · Reply

TheOriginalMoonMarket Dec. 1 at 12:05 AM

🛡️ Bucket 4: The "SWAN" List (Sleep Well At Night) Market crashing? Who cares. These companies have survived wars, recessions, and pandemics. They are the definition of defense. 🥤 $KO (Coca-Cola): A Dividend King. They have raised their dividend for over 60 years straight. 💊 $JNJ (Johnson & Johnson): A healthcare conglomerate. Triple-A credit rating (higher rated than the US Government). 🍔 $MCD (McDonald's): Real estate empire disguised as a burger joint. Recession-proof. 🧼 $PG (Procter & Gamble): Tide, Gillette, Pampers. People buy these products regardless of the economy. Vibe: 🛡️ 😴 🧴 🍔

0 · Reply

MoneyGroupLLC Nov. 29 at 12:43 PM

Enter: $JNJ Calls Strike Price: $208 Expiry Date: DEC 19 2025 Buy in Price: $3.90 - $4.09 Sell Price: $6.79 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

TalkMarkets Nov. 28 at 11:10 PM

Dogs Of The #Dow Continue Outperforming Broader Market $JNJ $VZ $AMGN $CSCO $KO https://talkmarkets.com/content/etfs/dogs-of-the-dow-continue-outperforming-broader-market?post=541467

0 · Reply

cubie Nov. 28 at 5:26 PM

$PSKY ok psky pumper. the Fact you say breaking up the $WBD has less value is so Wrong. are you new and born yesterday? Scam Street LOVES BREAKUPS. see $JNJ stock after it divested kvue , stock soared! see $WDC after it spun off $SNDK , both stocks ripped!. So to say less value in breakup vs whole is proven completely wrong as those examples. Cant teach stupid.

1 · Reply

ZacksResearch Nov. 28 at 3:59 PM

Big oncology push from $JNJ — is this the catalyst the stock’s been waiting for? Sales are surging on strong drug launches and clear pipeline momentum, and that’s exactly what JNJ needs as it chases its ambitious $50B 2030 goal. Full breakdown here 👉 https://www.zacks.com/stock/news/2797167/jnjs-oncology-momentum-builds-as-it-chases-50b-goal-by-2030?cid=sm-stocktwits-2-2797167-teaser-22730&ADID=SYND_STOCKTWITS_TWEET_2_2797167_TEASER_22730

0 · Reply

ZacksResearch Nov. 28 at 2:59 PM

$JNJ's oncology ambitions: Is $50B sales by 2030 realistic? 🤔 🔬 Oncology sales surged 20.6% in the first nine months, driven by market growth & contributions from drugs like Darzalex, Erleada, and new launches. 💡 New FDA-approved drug Inlexzoh & M&A with Halda Therapeutics enhance the broader pipeline. Discover if JNJ can double sales in the next 5-6 years here 👉 https://www.zacks.com/stock/news/2797167/jnjs-oncology-momentum-builds-as-it-chases-50b-goal-by-2030?cid=sm-stocktwits-2-2797167-body-22726&ADID=SYND_STOCKTWITS_TWEET_2_2797167_BODY_22726

0 · Reply

BillionerOfKing Nov. 28 at 2:39 PM

$JNJ Current Stock Price: $206.81 Contracts to trade: $210 JNJ Nov 28 2025 Call Entry: $0.18 Exit: $0.26 ROI: 42% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Quantumup Nov. 28 at 11:48 AM

Mizuho⬆️ $ARQT's PT to $37 from $32 and reiterated at an Outperform rating. $AMGN $ABBV $JNJ $UCBJY BMY OGN BHC Mizuho said in its note: Although there is one month remaining in 4Q25, Zoryve prescription trends have been stronger-than-expected, leading us to increase our sales forecast. We raise total sales from ~$109M to~$113M (vs. ~$110M consensus) for 4Q25 and from $464M to $470M (vs. $467M consensus) for 2026, putting these estimates above consensus. We also have greater confidence in the potential of Zoryve to convert the steroidal market, and we raise our 2035 sales forecast from $1.54B to $1.65B. These changes increase our price target from $32 to $37. We reiterate Outperform on ARQT, as we see potential upside to our estimates.

0 · Reply

Clear123 Nov. 28 at 6:00 AM

$SPY short $JNJ you lemmings

0 · Reply

Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)

Nov 30, 2025, 6:30 AM EST - 1 day ago

3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio

MDT PFE

Nov 30, 2025, 4:05 AM EST - 1 day ago

2 Top Dividend Stocks to Buy and Hold

BMY

Nov 29, 2025, 8:02 AM EST - 2 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR

Nov 29, 2025, 1:45 AM EST - 2 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY

Nov 28, 2025, 7:50 AM EST - 3 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA

Nov 27, 2025, 6:30 AM EST - 4 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O

Nov 27, 2025, 4:01 AM EST - 4 days ago

Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years

HD O PFE

Nov 25, 2025, 5:20 AM EST - 6 days ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

PFE

Nov 21, 2025, 12:43 PM EST - 9 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 19, 2025, 12:24 PM EST - 11 days ago

Why Johnson & Johnson's Share Price Is Popping This Month

Nov 18, 2025, 4:21 PM EST - 12 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 13 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Nov 17, 2025, 6:07 PM EST - 13 days ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 1:17 PM EST - 13 days ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 8:29 AM EST - 14 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:15 AM EST - 14 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:07 AM EST - 14 days ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:05 AM EST - 14 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:00 AM EST - 14 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 14, 2025, 3:19 PM EST - 16 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Nov 14, 2025, 8:03 AM EST - 17 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Nov 13, 2025, 5:04 AM EST - 18 days ago

2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon

ISRG

Nov 13, 2025, 3:55 AM EST - 18 days ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV

Nov 12, 2025, 11:01 AM EST - 18 days ago

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.

CVS

Nov 11, 2025, 1:41 PM EST - 19 days ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:51 PM EST - 19 days ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 6:26 AM EST - 21 days ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 10, 2025, 4:15 AM EST - 21 days ago

Got $1,000? Here Are the Smartest Dividend Stocks to Start With.

AWR BDX GPC KO MZTI NWN PG

Nov 7, 2025, 12:57 PM EST - 23 days ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 5:40 AM EST - 24 days ago

Johnson & Johnson: Dividends Don't Lie

Nov 6, 2025, 5:07 PM EST - 24 days ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 9:54 AM EST - 24 days ago

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 7:34 AM EST - 25 days ago

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:30 AM EST - 25 days ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 5, 2025, 4:50 PM EST - 25 days ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 3, 2025, 6:15 AM EST - 4 weeks ago

Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?

KVUE

Nov 1, 2025, 10:25 AM EDT - 4 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Oct 29, 2025, 8:05 AM EDT - 4 weeks ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 5:11 AM EDT - 4 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

Oct 28, 2025, 6:15 PM EDT - 4 weeks ago

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

Oct 28, 2025, 9:25 AM EDT - 4 weeks ago

J&J Stock Can Fall

Oct 28, 2025, 9:13 AM EDT - 4 weeks ago

Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks

KVUE

Oct 27, 2025, 10:45 AM EDT - 4 weeks ago

3 Healthcare Stocks to Buy Hand Over Fist in October

ISRG MRK

Oct 27, 2025, 8:00 AM EDT - 5 weeks ago

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

Oct 27, 2025, 7:30 AM EDT - 5 weeks ago

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Oct 27, 2025, 7:30 AM EDT - 5 weeks ago

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Oct 24, 2025, 6:32 PM EDT - 5 weeks ago

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Oct 24, 2025, 8:00 AM EDT - 5 weeks ago

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Oct 24, 2025, 4:30 AM EDT - 5 weeks ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ LRCX

FrankieSmilez Dec. 1 at 7:55 AM

1 · Reply

TheOriginalMoonMarket Dec. 1 at 12:05 AM

0 · Reply

MoneyGroupLLC Nov. 29 at 12:43 PM

0 · Reply

TalkMarkets Nov. 28 at 11:10 PM

Dogs Of The #Dow Continue Outperforming Broader Market $JNJ $VZ $AMGN $CSCO $KO https://talkmarkets.com/content/etfs/dogs-of-the-dow-continue-outperforming-broader-market?post=541467

0 · Reply

cubie Nov. 28 at 5:26 PM

1 · Reply

ZacksResearch Nov. 28 at 3:59 PM

0 · Reply

ZacksResearch Nov. 28 at 2:59 PM

0 · Reply

BillionerOfKing Nov. 28 at 2:39 PM

0 · Reply

Quantumup Nov. 28 at 11:48 AM

0 · Reply

Clear123 Nov. 28 at 6:00 AM

$SPY short $JNJ you lemmings

0 · Reply

Clear123 Nov. 28 at 5:59 AM

$JNJ About time to die

0 · Reply

TalkMarkets Nov. 27 at 9:24 PM

#Healthcare's Epic Rally $JNJ $LLY $MRK $REGN $XLV https://talkmarkets.com/content/stocks--equities/health-cares-epic-rally?post=541189

0 · Reply

MoneyGroupLLC Nov. 27 at 12:41 PM

Enter: $JNJ Calls Strike Price: $208 Expiry Date: DEC 19 2025 Buy in Price: $4.25 - $4.46 Sell Price: $6.93 Profit : +63% (Turn every $1 into $1.63) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ColinWolf981 Nov. 26 at 9:12 AM

$JNJ trends in the healthcare sector. AMBR stated that its Q3 earnings webcast is scheduled for November 26. https://viavid.webcasts.com/starthere.jsp?ei=1743886&tp_key=bebae2bd4a

0 · Reply

rockysat111 Nov. 26 at 4:25 AM

$JNJ all time high 🎢

0 · Reply

MoneyGroupLLC Nov. 26 at 2:57 AM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: DEC 19 2025 Buy in Price: $1.91 - $1.95 Sell Price: $3.30 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HedgeAlerts Nov. 26 at 2:31 AM

Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $205.00 Put · DEC 05, 2025 Exp Entry Price: $1.70 - $1.81 Exit Price Target: $4.06 Profit Margin: +139% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Nov. 25 at 11:58 PM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $208 Call | Enter: $1.18 Exit: $1.86 | Profit: 57.89% ROI | https://1ightning.com

0 · Reply

TechTraderGrok Nov. 25 at 10:57 PM

Sold $JNJ at $206.72 (+6.7%). From Grok: "Exiting long JNJ position from $193.83 entry 10 bars ago to secure substantial gains near all-time highs around $207 with overbought RSI above 80, elevated stochastic near 99, and MACD histogram peaking, amid no fresh bullish catalysts and potential for short-term pullback despite intact uptrend." https://www.techtrader.ai/grokwall/?post=15686&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

LiquidThetaOptions Nov. 25 at 9:31 PM

💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $13.47- $16.46 Scale out: $52.37-$89.77 Profit Potential : 281% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

BEATOFtheMARKET Nov. 25 at 7:51 PM

$JKHY $JNJ $JOBX $JPM $JPST

0 · Reply

Austero Nov. 25 at 6:18 PM

$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK

1 · Reply

Market Cap	498.53B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	20.00
Forward PE	19.10
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	5,638,200
Avg Vol	9,088,680
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	93%
Beta	0.38
Analysts	Strong Sell
Price Target	$203.50